Summary
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript
Neurogene: From Speculation To Execution With NGN-401
Neurogene has transitioned into a data-driven, registrational-stage company with NGN-401 showing strong safety and efficacy for Rett syndrome. NGNE's disciplined financial management provides a cash runway through Q1 2028, allowing focused investment in its lead asset and minimizing dilution risk. NGN-401's clinical data demonstrate durable, multi-domain functional gains and a favorable safety profile, positioning it as a potential first-in-class therapy.
Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript
Neurogene Inc. ( NGNE ) Stifel 2025 Healthcare Conference November 12, 2025 4:40 PM EST Company Participants Rachel McMinn - Founder, Executive Chair & CEO Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Paul Matteis Stifel, Nicolaus & Company, Incorporated, Research Division Thank you very much. Happy to be introducing Rachel McMinn, Founder and CEO of Neurogene, who has some new fresh data to talk us through for NGN-401 in Rett syndrome.
Neurogene Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 40 | $597.82 | $1,575.09 | $977.27 | 163.47% |
 John H. Burbank III Passport Capital LLC | 991,691 | $13.62M | $38.73M | $25.11M | 184.37% |
 Joseph Castro Nuveen LLC | 25,210 | $329,998.41 | $989,870.65 | $659,872.24 | 199.96% |
 Li Peng China Universal Asset Management Co. Ltd. | 2,749 | $62,184.92 | $107,650.84 | $45,465.92 | 73.11% |
 Michael Byun SageView Advisory Group LLC | 45 | $927 | $1,710.9 | $783.9 | 84.56% |
Neurogene Inc. (NGNE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Neurogene Inc. ever had a stock split?
Neurogene Inc. Profile
| Biotechnology Industry | Healthcare Sector | Rachel L. McMinn CEO | NASDAQ (NMS) Exchange | 64135M105 CUSIP |
| US Country | 131 Employees | - Last Dividend | 19 Dec 2023 Last Split | - IPO Date |
Overview
Neurogene Inc. is a biotechnology firm focused on creating genetic medicines for those suffering from rare neurological conditions. Based in New York, New York, the organization is leveraging the latest in genetic therapy technology to develop treatments that target the genetic roots of these diseases. Their efforts are supported by strategic license agreements with prominent research institutions and companies like The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC, reflecting a collaborative approach to tackling some of the most challenging conditions in the medical field today. Through its dedicated research and clinical trials, Neurogene Inc. is poised to offer new hope to patients and families affected by neurological disorders that have limited treatment options.
Products and Services
Neurogene Inc. is actively developing a portfolio of genetic medicine products, each designed to address the complexities of rare neurological disorders. Here are their key product candidates:
- NGN-401: A cutting-edge genetic therapy vehicle, NGN-401 uses an adeno-associated virus 9 (AAV9) to deliver its therapeutic payload. It's currently in Phase 1/2 clinical trial targeting the treatment of Rett syndrome, a rare neurological disorder that predominantly affects girls and can lead to severe cognitive, sensory, emotional, motor, and autonomic functioning issues. The use of AAV9 is significant due to its proven capability to cross the blood-brain barrier and deliver genetic material directly to the brain, offering a potential route to correct the underlying genetic conditions causing Rett syndrome.
- NGN-101: As a conventional gene therapy candidate, NGN-101 is instrumental in targeting CLN5 Batten disease, a fatal, inherited disorder of the nervous system that typically begins in childhood. Currently in Phase 1/2 clinical trials, NGN-101 aims to replace the defective CLN5 gene in patients with a healthy copy, potentially halting or slowing the disease's progression. Batten disease is characterized by vision loss, cognitive impairment, seizures, and progressive motor decline. By addressing the genetic basis of the disease, NGN-101 presents a hopeful avenue for treatment.
